Simplifying Global Compliance
FDAnews Drug Daily Bulletin
FDA Granted Approval for 32-mg Exalgo Tablets
Aug. 28, 2012
Zalicus announced the the FDA has granted approval for the supplemental new drug application filed by Mallinckrodt, a subsidiary of Covidien, for the 32-mg dose strength of Exalgo extended-release tablets, for the management of moderate to severe pain in opioid-tolerant patients requiring continuous opioid analgesia for an extended period of time.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing